Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Files for Approval of its EV71 Vaccine

publication date: May 30, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech reported the Beijing Drug Administration has accepted the company's filing of a New Drug Application for its novel enterovirus 71 vaccine. The vaccine, which completed its Phase III trial in March, achieved a 95% efficacy against Hand, Foot and Mouth Disease. Yesterday, Beijing Vigoo Biological, a China National Biotec unit, published data in The Lancet, revealing its EV71 vaccine had a near-identical 90% efficacy. More details....

Stock Symbol: (NSDQ: SVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
Shanghai, China
April 14-15, 2015

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors